Searchable abstracts of presentations at key conferences in endocrinology

ea0065p151 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

A post implementation audit of a local Chromogranin A service – a step towards individualised patient care

Frank Amy , Smith Karen

Background: Neuroendocrine tumours are rare tumours that arise from neuroendocrine cell types which are widespread throughout the body. These tumours can develop in many different organs and secrete a variety of hormones making biochemical monitoring of treatment/progression challenging. Previously patients at Beatson West of Scotland Cancer Centre were monitored using either a full gut hormone profile (GHP) or chromogranin A and B (CGs) measured at Charing Cross Hospital. A n...

ea0059p062 | Clinical biochemistry | SFEBES2018

Urine steroid profiles: what can they do for me?

Syme Neil , Smith Karen

A recent audit of the urine steroid profile (USP) service at Glasgow Royal Infirmary (GRI) revealed that up to 25% of requests are made inappropriately, or without any clinical information. In contrast to the majority of biochemical testing, USP analysis is very labour intensive, and interpretation of results requires both quantitative and qualitative assessment of the profile. Adequate clinical information is essential to generate a complete report, as a number of steroids fo...

ea0059p114 | Neoplasia, cancer & late effects | SFEBES2018

The analytical validation and clinical implications of introducing a chromogranin A referral service within Scotland

Wadsworth John , Smith Karen

Background: Chromogranin A is an acidic 48 kDa glycoprotein originating from the chromaffin granules of most neuroendocrine cell types. In health chromogranin A is released as a pro-hormone together with other peptide hormones in response to stimulation. In disease larger quantities of Chromogranin A are produced by neuroendocrine derived tumours thus allowing its use as a tumour marker. Due to the different clinical scenarios for measuring Chromogranin A requesting practices ...

ea0059p214 | Thyroid | SFEBES2018

Evaluation of a high sensitivity thyroglobulin assay for use in patients following total thyroidectomy and radioiodine ablation treatment

Frank Amy , Smith Karen

Background/aims: Thyroglobulin (Tg) is used for monitoring patients who have undergone total thyroidectomy (TT) and radioiodine (RAI) ablation therapy for thyroid cancer. The current method is the Siemens Immulite assay with limit of quantification of 2 ng/mL following in-house evaluation. Recent guidelines suggest the use of high sensitivity Tg (hs-Tg) as an alternative to TSH stimulated Tg levels. The aim is to evaluate the hs-Tg Beckman Access II assay with a stated functio...

ea0059p022 | Adrenal and steroids | SFEBES2018

A review of short synacthen test results: what is the cut-off?

Frank Amy , Perry Colin , Smith Karen

Background/aims: The short synacthen test (SST) is a dynamic function test used to assess the hypothalamic pituitary adrenal axis. Interpretation requires consideration of sample timing and cortisol method. Currently the 30 minutes post-synacthen cortisol (CORT30) at NHS Greater Glasgow and Clyde (NHS GGC) is >450 nmol/l measured on the Abbott Architect. A large reference range study published a cut-off of >430 nmol/l for this method. This audit aims to document clinic...

ea0013p117 | Comparative | SFEBES2007

Performance characteristics of an intact PTH recently developed for the Abbott Architect immunoassay analyser

Smith Karen , Wallace Mike , Louden Ian

Concerns on the noncomparibility of intact parathyroid hormone (iPTH) methods have recently been voiced (Cantor T et al; Clin Chem 2006, 52, 1771–6). It is therefore important that any new iPTH immunoassays are thoroughly validated before routine use. We describe performance characteristics for an iPTH immunoassay on the ARCHITECT 8200i analyser as compared with iPTH measurement on the Diasorin LIAISON platform. Potassium EDTA plasma samples (n=80) we...

ea0094p2 | Adrenal and Cardiovascular | SFEBES2023

Comparison of aldosterone measurements during saline suppression tests by immunoassay and liquid chromatography tandem mass spectrometry methods

Frank Amy , Johnston Susan , Smith Karen

Background: Primary aldosteronism is an increasingly recognised cause of hypertension, caused by excess aldosterone secretion. Screening and confirmatory tests such as saline suppression tests (SST) require accurate measurements of aldosterone and use of appropriate cut-offs. Many laboratories have chosen liquid chromatography tandem mass spectrometry (LC-MSMS) methods as issues of poor specificity have been reported for immunoassay methods. During the validat...

ea0049gp104 | Diabetes therapy & complications 2 | ECE2017

Non-stimulated c-peptide is independently associated with requirement at 1 year for insulin therapy in patients with diabetes: a retrospective cohort study of 872 patients

Leighton Emma , Smith Karen , Sainsbury Christopher , Jones Gregory

Introduction: C-peptide is frequently used in clinical practice to estimate insulin secretion, and guide need for future insulin treatment. Present practice is based on studies with small patient numbers.Aim: To explore the association between non-stimulated c-peptide and progression to insulin therapy in patients with diabetes.Patients and Methods: 1971 patients with c-peptide measurements were identified (February 2007–Decem...

ea0038p319 | Pituitary | SFEBES2015

The accuracy of bilateral inferior petrosal sinus cannulation and usefulness of prolactin adjustment in one Scottish centre

Devine Kerri , Smith Karen , Robertson Iain , Perry Colin , Freel Marie

Bilateral inferior petrosal sinus sampling (BIPSS) is the gold standard investigation in Cushing’s disease for identifying the pituitary as the ACTH source. This technique aims to demonstrate a gradient of central:peripheral ACTH levels of >2:1 in such patients, or >3:1 after CRH stimulation. In patients without significant pituitary MRI abnormalities this facilitates neurosurgical exploration.The test is limited by difficulties in achieving...

ea0074ncc53 | Highlighted Cases | SFENCC2021

A case of heterophile antibody interference causing a falsely positive thyroglobulin in a patient with non-relapsing thyroid carcinoma

Dewdney Charlotte , McDonald Lindsay , Isa Aidah , Smith Karen , Muir Kenneth

Case History: We report the case of a 59-year-old lady with a persistently elevated serum thyroglobulin following a total thyroidectomy for multifocal papillary thyroid carcinoma. She subsequently underwent radioiodine therapy following which her serum thyroglobulin remained elevated. However, it was later found to be almost undetectable at 0.3 μg/l after a change in laboratory method. This discrepancy prompted further investigation, and repeat analysis using the original assa...